Stereotactic body radiation therapy for nonpulmonary primary tumors

Expert Review of Anticancer Therapy

Volumn 8, Issue 12, 2008, Pages 1939-1951

  Lo, Simon S ^a   Cardenes, Higinia R ^b   Teh, Bin S ^c   Fakiris, Achilles J ^d   Henderson, Mark A ^d   Papiez, Lech ^e   McGarry, Ronald C ^f   Wang, Jian Z ^a   Li, Kaile ^a   Mayr, Nina A ^a   Timmerman, Robert D ^e  

^a OHIO STATE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Nonpulmonary; Primary tumor; Stereotactic body radiation therapy

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; GEMCITABINE; LIVER ENZYME;

BRACHYTHERAPY; BRAIN TUMOR; CANCER CONTROL; CANCER INCIDENCE; CANCER LOCALIZATION; CLINICAL TRIAL; COMPUTER ASSISTED SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CRYOTHERAPY; DIAGNOSTIC ACCURACY; DOSIMETRY; DUODENUM PERFORATION; DUODENUM STENOSIS; GASTROINTESTINAL TOXICITY; HUMAN; IMAGE QUALITY; IMMOBILIZATION; INTENSITY MODULATED RADIATION THERAPY; KIDNEY CARCINOMA; LIVER CANCER; LIVER CELL CARCINOMA; NAUSEA; NEPHRECTOMY; NONHUMAN; NONPULMONARY PRIMARY TUMOR; PANCREAS CANCER; PHYSICS; PRIMARY TUMOR; PROSTATE CANCER; RADIATION DOSE; REVIEW; SPINE TUMOR; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT PLANNING; TUMOR VOLUME; NEOPLASM; RADIOSURGERY;

HUMANS; NEOPLASMS; RADIOSURGERY;

EID: 61449426253     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.12.1939     Document Type: Review

References (57)

1. Chang BK, Timmerman RD. Stereotactic body radiation therapy: a comprehensive review. Am. J. Clin. Oncol. 30(6), 637-644 (2007).
2. Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic body radiation therapy in multiple organ sites. J. Clin. Oncol. 25(8), 947-952 (2007).
3. Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 70(3), 847-852 (2008).
4. Benedict SH, Lin PS, Zwicker RD, Huang DT, Schmidt-Ullrich RK. The biological effectiveness of intermittent irradiation as a function of overall treatment time: development of correction factors for linac-based stereotactic radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 37(4), 765-769 (1997).
5. Kavanagh BD, Timmerman RD, Benedict SH et al. How should we describe the radioblologic effect of extracranial stereotactic radiosurgery: equivalent uniform dose or tumor control probability? Med. Phys. 30(3), 321-324 (2003).
6. Lo SS, Fakiris AJ, Papiez L et al. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer. Expert Rev. Anticancer Ther. 8(1), 87-98 (2008).
7. Lotan Y, Stanfield J, Cho LC et al. Efficacy of high dose per fraction radiation for implanted human prostate cancer in a nude mouse model. J. Urol. 175(5), 1932-1936 (2006).
8. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int. J. Radiat. Oncol. Biol. Phys. 67(4), 1099-1105 (2007).
9. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94(2), 153-156 (2001).
10. El-Serag HB and Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340(10), 745-750 (1999).
11. Kelsey CR, Schefter T, Nash SR et al. Retrospective clinicopathologic correlation of gross tumor size of hepatocellular carcinoma: implications for stereotactic body radiotherapy. Am. J. Clin. Oncol. 28(6), 576-580 (2005).
12. Blomgren H, Lax I, Goranson H et al. Radiosurgery for tumors in the body: clinical experience using a new method. J. Radiosurg. 1, 63-74 (1998).
13. Herfarth KK, Debus J, Lohr F et al. Stereotactic single-dose radiation therapy of liver tumors: results of a Phase I/II trial. J. Clin. Oncol. 19(1), 164-170 (2001).
14. Wulf J, Guckenberger M, Haedinger U et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 45(7), 838-847 (2006).
15. Choi BO, Jang HS, Kang KM et al. Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. Jpn J. Clin. Oncol. 36(3), 154-158 (2006).
16. Tse RV, Hawkins M, Lockwood G et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J. Clin. Oncol. 26(4), 657-664 (2008).
17. Mendez Romero A, Wunderink W, Hussain SM et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution Phase I-II study. Acta Oncol. 45(7), 831-837 (2006).
18. Walsh L, Stanfield JL, Cho LC et al. Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur. Urol. 50(4), 795-800 (2006).
19. Beitler JJ, Makara D, Silverman P, Lederman G. Definitive high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am. J. Clin. Oncol. 27(6), 646-648 (2004).
20. Wersall PJ, Blomgren H, Lax I et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother. Oncol. 77(1), 88-95 (2005).
21. Svedman C, Sandstrom P, Pisa P et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 45(7), 870-875 (2006).
22. Ponsky LE, Mahadevan A, Gill IS, Djemil T, Novick AC. Renal radiosurgery: initial clinical experience with histological evaluation. Surg. Innov. 14(4), 265-269 (2007).
23. Teh B, Bloch C, Galli-Guevara M. The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed Imaging Interv. J. 3(1), e6 (2007).
24. Hoyer M, Roed H, Sengelov L et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother. Oncol. 76(1), 48-53 (2005).
25. Koong AC, Le QT, Ho A et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 58(4), 1017-1021 (2004).
26. Koong AC, Christofferson E, Le QT et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 63(2), 320-323 (2005).
27. Schellenberg D, Goodman KA, Lee F et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j. ijrobp.2008.01.051 (2008) (Epub ahead of print).
28. Lunsford LD, Niranjan A, Flickinger JC, Maitz A, Kondziolka D. Radiosurgery of vestibular schwannomas:. summary of experience in 829 cases. J. Neurosurg. 102(Suppl.), 195-199 (2005).
29. Petit JH, Hudes RS, Chen TT, Eisenberg HM, Simard JM, Chin LS. Reduced-dose radiosurgery for vestibular schwannomas. Neurosurgery 49(6), 1299-1306 (2001).
30. Flickinger JC, Koodziolka D, Niranjan A, Maitz A, Voynov G, Lunsford LD. Acoustic neuroma radiosurgery with marginal tumor doses of 12 to 13 Gy. Int. J. Radiat. Oncol. Biol. Phys. 60(1), 225-230 (2004).
31. Flickinger JC, Kondziolka D, Maitz AH, Lunsford LD. Gamma knife radiosurgery of imaging-diagnosed intracranial meningioma. Int. J. Radiat. Oncol. Biol. Phys. 56(3), 801-806 (2003).
32. Lee JY, Kondziolka D, Flickinger JC, Lunsford LD. Radiosurgery for intracranial meningiomas. Prog. Neurol. Surg. 20, 142-149 (2007).
33. Lee JY, Niranjan A, McInerney J, Kondziolka D, Flickinger JC, Lunsford LD. Stereotactic radiosurgery providing long-term tumor control of cavernous sinus meningiomas. J. Neurosurg. 97(1), 65-72 (2002).
34. Lo SS, Chang EL, Yamada Y, Sloan AE, Suh JH, Mendel E. Stereotactic radiosurgery and radiation therapy for spinal tumors. Expert Rev. Neurother. 7(1), 85-93 (2007).
35. Gerszten PC, Ozhasoglu C, Burton SA et al. CyberKnife frameless single-fraction stereotactic radiosurgery for benign tumors of the spine. Neurosurg. Focus 14(5), e16 (2003).
36. Gerszten PC, Burton SA, Ozhasoglu C, McCue KJ, Quinn AE. Radiosurgery for benign intradural spinal tumors. Neurosurgery 62(4), 887-895 (2008).
37. Dodd RL, Ryu MR, Kamnerdsupaphon P. Gibbs IC, Chang SD Jr, Adler JR Jr. CyberKnife radiosurgery for benign intradural extramedullary spinal tumors. Neurosurgery 58(4), 674-685 (2006).
38. Sahgal A, Chou D, Ames C et al. Image-guided robotic stereotactic body radiotherapy for benign spinal tumors: the University of California, San Francisco preliminary experience. Technol Cancer Res. Treat. 6(6), 595-604 (2007).
39. Martinez AA, Pataki I, Edmundson G, Sebastian E, Brabbins D, Gustafson G. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int. J. Radiat. Oncol. Biol. Phys. 49(1), 61-69 (2001).
40. Grills IS, Martinez AA, Hollander M et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared with low dose rate palladium seeds. J. Urol. 171(3), 1098-1104 (2004).
41. Yoshioka Y, Nose T, Yoshida K et al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a Phase I/II clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 48(3), 675-681 (2000).
42. Yoshioka Y, Nose T, Yoshida K et al. High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity. Int. J. Radiat. Oncol. Biol. Phys. 56(1), 213-220 (2003).
43. Stillwagon GB, Order SE, Guse C et al. 194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study. Int. J. Radiat. Oncol. Biol. Phys. 17(6), 1223-1229 (1989).
44. Abrams RA, Pajak TF, Haulk TL, Flam M, Asbell SO. Survival results among patients with α-fetoprotein-positive, unresectabte hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center. Cancer J. Sci. Am. 4(3), 178-184 (1998).
45. Dawson LA, McGinn CJ, Normolle D et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J. Clin. Oncol. 18(11), 2210-2218 (2000).
46. Liu MT, Li SH, Chu TC et al. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn J. Clin. Oncol. 34(9), 532-539 (2004).
47. Seong J, Park HC, Han KH, Chon CY. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int. J. Radiat. Oncol. Biol. Phys. 55(2), 329-336 (2003).
48. Mornex F, Girard N, Beziat C et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies - mature results of the French Phase II RTF-1 trial. Int. J. Radiat. Oncol. Biol. Phys. 66(4), 1152-1158 (2006).
49. Antonelli A, Cozzoli A, Nicolai M et al. Nephron-sparing surgery versus radical nephrectomy in the treatment of intracapsular renal cell carcinoma up to 7 cm. Eur. Urol. 53(4), 803-809 (2008).
50. Margulis V, Tamboli P, Jacobsohn KM, Swanson DA, Wood CG. Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma. BJU Int. 100(6), 1235-1239 (2007).
51. Lerner SE, Hawkins CA, Blute ML et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery, 1996. J. Urol. 167(2 Pt 2), 884-889 (2002).
52. Lo SS, Chang EL, Suh JH. Stereotactic radiosurgery with and without whole-brain radiotherapy for newly diagnosed brain metastases. Expert Rev. Neurother. 5(4), 487-495 (2005).
53. Teh BS, Bloch C, Paulino AC et al. Pathologic complete response in renal cell carcinoma brain metastases treated with stereotactic radiosurgery. Clin. Genitourin. Cancer 5(5), 334-337 (2007).
54. Gerszten PC, Burton SA, Welch WC et al. Single-fraction radiosurgery for the treatment of spinal breast metastases. Cancer 104(10), 2244-2254 (2005).
55. Gerszten PC, Burton SA, Quinn AE, Agarwala SS, Kirkwood JM. Radiosurgery for the treatment of spinal melanoma metastases. Stereotact. Funct. Neurosurg. 83(5-6), 213-221 (2005).
56. Gerszten PC, Burton SA, Ozhasoglu C et al. Stereotactic radiosurgery for spinal metastases from renal cell carcinoma. J. Neurosurg. Spine 3(4), 288-295 (2005).
57. Pollock BE. Management of vestibular schwannomas that enlarge after stereotactic radiosurgery: treatment recommendations based on a 15 year experience. Neurosurgery 58(2), 241-248 (2006).